Pacritinib

From Wikipedia, the free encyclopedia

Template:Short description Template:Cs1 config Template:DMCA Template:DMCA Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Pacritinib
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Clinical data
Trade namesVonjo
Other namesSB1518
License dataPage Template:Plainlist/styles.css has no content.
Routes of
administration		By mouth
ATC codePage Template:Plainlist/styles.css has no content.
Legal status
Legal statusPage Template:Plainlist/styles.css has no content.
Identifiers
  • (16E)-11-[2-(1-Pyrrolidinyl)ethoxy]-14,19-dioxa-5,7,26-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
FormulaC28H32N4O3
Molar mass472.589 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
  • c1cc2cc(c1)-c3ccnc(n3)Nc4ccc(c(c4)COC/C=C/COC2)OCCN5CCCC5
  • InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+
  • Key:HWXVIOGONBBTBY-ONEGZZNKSA-N
Data page
Template:Infobox drug/data page link

Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis.[1][2][3][4]

It is a macrocyclic protein kinase inhibitor. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3\CD135 (FLT3).

Common side effects include diarrhea, low platelet counts, nausea, anemia, and swelling in legs.[2]

Medical uses

Pacritinib in indicated to treat adults who have a rare form of a bone marrow disorder known as intermediate or high-risk primary or secondary myelofibrosis and who have platelet (blood clotting cells) levels below 50,000/μL.[1][2]

History

The effectiveness and safety of pacritinib were demonstrated in a study that included 63 participants with intermediate or high-risk primary or secondary myelofibrosis and low platelets who received pacritinib 200 mg twice daily or standard treatment.[2] Effectiveness was determined based upon the proportion of participants who had a 35% or greater spleen volume reduction from baseline to week 24.[2] Nine participants (29%) in the pacritinib treatment group had a 35% or greater spleen volume reduction, compared to one participant (3%) in the standard treatment group.[2]

The U.S. Food and Drug Administration (FDA) granted the application for pacritinib priority review, fast track, and orphan drug designations.[2][5]

Society and culture

Names

Pacritinib is the International nonproprietary name (INN).[6][7]

References

Page Template:Reflist/styles.css has no content.

  1. ^ a b c Page Module:Citation/CS1/styles.css has no content."Vonjo- pacritinib capsule". DailyMed. 7 March 2022. Retrieved 24 March 2022.
  2. ^ a b c d e f g h Page Module:Citation/CS1/styles.css has no content."FDA approves drug for adults with rare form of bone marrow disorder". U.S. Food and Drug Administration. 1 March 2022. Archived from the original on 1 March 2022. Retrieved 3 March 2022. Public Domain This article incorporates text from this source, which is in the public domain.
  3. ^ Page Module:Citation/CS1/styles.css has no content.Mascarenhas J (August 2022). "Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia". Expert Review of Hematology. 15 (8): 671–684. doi:10.1080/17474086.2022.2112565. PMID 35983661.
  4. ^ Page Module:Citation/CS1/styles.css has no content.Yang DH, Lu Q, Zhu Z, Huang G, Young K (December 2022). "Pacritinib for myelofibrosis in adults with thrombocytopenia". Drugs of Today. 58 (12): 577–589. doi:10.1358/dot.2022.58.12.3474538. PMID 36651066.
  5. ^ Page Module:Citation/CS1/styles.css has no content.Lamb YN (May 2022). "Pacritinib: First Approval". Drugs. 82 (7): 831–838. doi:10.1007/s40265-022-01718-y. PMID 35567653.
  6. ^ Page Module:Citation/CS1/styles.css has no content."International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 104" (PDF). WHO Drug Information. 24 (4): 386. 2010. hdl:10665/74579.
  7. ^ Page Module:Citation/CS1/styles.css has no content."International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 66". WHO Drug Information. 25 (3). 2011. hdl:10665/74683.

Template:Extracellular chemotherapeutic agents Template:Cytokine receptor modulators Lua error in mw.title.lua at line 404: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal').

Template:Asbox

Retrieved from "https://cosmopedia.co/index.php?title=Pacritinib&oldid=12691194"